About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Any statements contained in this press release that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements represent our management's judgment regarding
future events. The Company does not undertake any obligations to update any
forward-looking statements whether as a result of new information, future
events or otherwise. Our actual results could differ materially from those
discussed herein due to several factors including the success and timing of
a commercial partnership and our ability to obtain and maintain regulatory
approval and labeling of our product candidates; our plans to develop and
commercialize our product candidates; the loss of key scientific or
management personnel; the size and growth of potential markets for our
product candidates and our ability to serve those markets; regulatory
developments in the U.S. and foreign countries; the rate and degree of
market acceptance of any future products; the accuracy of our estimates
regarding expenses, future revenues and capital requirements; our ability
to obtain financing on terms acceptable to us; our ability to obtain and
maintain intellectual property protection for our product candidates; the
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved